Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself ...

Patel, Trump’s nominee to be FBI director, was paid $25,000 last year by a film company that has promoted anti-Western views ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Boris Becker's ex-wife Lilly looked on cloud nine as she touched down at Frankfurt Airport on Wednesday after winning the ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...